Skip to content
FDAMedicines

Sunny Pharmtech, Inc. Issues Voluntary Nationwide Recall of Cyclophosphamide for Injection, USP to the User Level Due to the Presence of Particulate Matter

FDA recall n-sunny-pharmtech-inc-issues-voluntary-nationwide-recall-cyclophosphamide-injectio ·

Build snapshot. Collected , once, when this site was built. It is not a live feed.

Check my lot or code

Is yours in this recall?

Type the lot, batch, date code, model number or UPC printed on the product. It is compared here, in your browser, with the codes this notice lists. It stays in this page: it is not added to the address.

General information on recalls from the agency: U.S. Food and Drug Administration (opens in a new tab).

What the agency says to do

FDA’s record gives no instruction for consumers.

Note from Recalls Watch, not agency text

Why it was recalled

Presence of particulate matter identified as steel
Text from FDA, unedited.

The recalled product

July 24, 2026 - Taoyuan City, Taiwan - Sunny Pharmtech, Inc is voluntarily recalling three lots of Cyclophosphamide for Injection, USP, 1g/vial and 2g/vial, to the User Level due to the presence of particulate matter identified as steel. To date, no adverse events or injuries associated with this pa
Text from FDA, unedited.

Company announcement, as FDA publishes it

July 24, 2026 - Taoyuan City, Taiwan - Sunny Pharmtech, Inc is voluntarily recalling three lots of Cyclophosphamide for Injection, USP, 1g/vial and 2g/vial, to the User Level due to the presence of particulate matter identified as steel. To date, no adverse events or injuries associated with this particulate matter issue have been reported.

Risk Statement: There is a reasonable probability for serious adverse events, including death, should a patient receive intravenous infusion of product found to contain particulate matter. For the population most at risk, cancer patients who are likely to have numerous pre-existing comorbidities and may be immunosuppressed due to concomitant or prior treatment and nutritional issues related to their cancer, complications can include phlebitis, granuloma, and occlusion or life-threatening thromboembolic events.

Cyclophosphamide for Injection, USP is indicated for treatment of malignant diseases (malignant lymphomas; Hodgkin’s disease, lymphocytic lymphoma, mixed-cell type lymphoma, histiocytic lymphoma, Burkitt’s lymphoma; multiple myeloma, leukemias, mycosis fungoides, neuroblastoma, adenocarcinoma of ovary, retinoblastoma, breast carcinoma) and minimal change nephrotic syndrome in pediatric patients (biopsy-proven minimal change nephrotic syndrome patients who failed to adequately respond to or are unable to tolerate adrenocorticosteroid therapy).

The affected Product is packaged as 1 g/vial, one 50 mL single-dose vial in a carton (NDC 81298-8112-1) and as a 2 g/vial, one 100 mL single-dose vial in a carton (NDC 81298-8114-1). The affected product was distributed to wholesalers, distributors, hospitals and pharmacies from May 2024 to October 2024 and can be identified using the information below. The three recalled lots (C23019V1, C24015V1, V24010V1) will remain within expiry until October 2026, April 2027, and March 2027, respectively.

Sunny PharmTech has notified FDA and its distributor, Cardinal Health, of this recall action and is coordinating with Long Grove Pharmaceuticals, LLC and Cardinal Health to notify pharmacies, hospitals, and other healthcare providers and to coordinate the return, reconciliation and destruction of the three lots of recalled product in accordance with the recall strategy.

Pharmacies, hospitals, and other healthcare providers that have the recalled product should immediately stop use and dispensing, and quarantine all affected product inventory, and follow the instructions in the recall notification for arranging return of the affected lots to Cardinal Health.

Consumers with questions regarding this recall may contact Sunny Pharmtech, Inc. at 886-3-4809168, Ext. 7205 or ra@sunnypharmtech.com , Monday through Friday from 9AM to 5PM GMT+8. Consumers should contact their physician or healthcare provider if they have experienced any problem that may be related to taking or using this drug product and should not stop or change prescribed treatment without consulting a healthcare professional.

Adverse reactions or quality problems experienced with the use of this product may be reported to FDA's MedWatch Adverse Event Reporting Program as follows:

This recall is being conducted with the knowledge of, and in coordination with, the U.S. Food and Drug Administration.

Text from FDA (the company’s words), unedited.
  • Cyclophosphamide for Injection, USP

    Lot or code
    Dosage Form / Package: 1 g/vial, 50mL vial; NDC: 81298-8112-1; Lot Number: C23019V1; Expiration Date: Oct-2026 | Dosage Form / Package: 1 g/vial, 50mL vial; NDC: 81298-8112-1; Lot Number: C24015V1; Expiration Date: Apr-2027 | Dosage Form / Package: 2 g/vial, 100 mL vial; NDC: 81298-8114-1; Lot Number: V24010V1; Expiration Date: Mar-2027

Source

Issued by
U.S. Food and Drug Administration
Firm
Sunny Pharmtech, Inc.

Check all notices that name this firm in the directory of recalls by brand and manufacturer. This notice is in these lists: Firm: Sunny Pharmtech, Inc., Medicine: Cyclophosphamide, Month: July 2026, Week 2026-W30. Browse more medicines recalls, or check another notice by its number in the recall number lookup.

About this recall

What is the hazard?

FDA states: “Presence of particulate matter identified as steel”

What should I do if I have this product?

FDA’s record gives no instruction for consumers. The official report is linked on this page.

How do I know if my product is included?

Compare the lot or code printed on your product with the codes FDA lists on this notice, product by product.

How does the code check on this page work?

You type the lot, batch, date code, model number or UPC from your package and the page compares it, in your browser, with the codes FDA lists on this notice. It reports a match, a possible match (your code is part of a longer listed code) or no match. It only compares text: a notice that describes products by dates, sizes or “all lots” cannot be compared, so “no match” does not clear a product. The comparison runs in your browser and the page does not send the code anywhere, and the code stays out of the page address. Only if you press “Copy link to this result” is a link made that carries it, and whoever opens that link requests that address from this site.

When was this recall published?

FDA published this company announcement on July 24, 2026.

Other notices of Sunny Pharmtech, Inc.